Abstract
Purpose Individuals with diabetes carry an increased risk for adverse clinical outcome in case of SARS-CoV-2 infection. The purpose of this study was to evaluate whether this risk is, at least in part, modulated by an increase of thromboembolic complications.
Methods We prospectively followed 169 hospitalized patients with confirmed COVID-19 pneumonia admitted to the Internal Medicine Units of San Raffaele Hospital. We analysed inflammation and tissue damage biomarkers, hemostatic parameters, thrombotic events and clinical outcome according to the presence of hyperglycaemia or diagnosed diabetes.
Results Among 169 patients, 51 (30.2%) had diabetes. Diabetes and hyperglycemia were associated with increased inflammation and tissue damage circulating markers, higher D-dimer levels, increased prothrombin time and lower antithrombin III activity. Forty-eight venous and 10 arterial thrombotic events were identified in 49 (29%) patients. Diabetes (HR 2.71, p=0.001), fasting blood glucose (HR 4.32, p<0.001), glucose variability (HR 1.6, p < 0.009), presence of antiphospholipid antibodies (HR 4.18, p=0.033) and the positivity for virus spike protein antibodies (RBD IgG, HR 3.93, p=0.006; S1/S2 IgG, HR 3.36, p=0.027 and RBD IgA, HR 4.98, p=0.001) were all associated with an increased risk of thromboembolic complication. Thromboembolic complications significantly increased the risk for an adverse clinical outcome only in the presence of diabetes (HR 3.05, p=0.01) or hyperglycaemia (HR 3.07, p=0.015).
Conclusions Thromboembolism risk is higher among patients with diabetes and COVID-19 pneumonia and is associated to poor clinical outcome. In case of SARS-Cov-2 infection patients with diabetes could be considered for a more intensive prophylactic anticoagulation regimen.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04318366
Funding Statement
This work was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (COVID-2020-12371617).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of IRCCS San Raffaele Scientific Institute, Milan, Italy. (protocol n 34/int/2020; NCT04318366).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declaration of interests. The authors have no conflict of interest to disclose in relation to the topic of this manuscript. This work was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (COVID-2020-12371617).
Data Availability
Some or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
